IMPAX LABS
GenericsIMPAX LABS is a generic drug manufacturer focused on Neurology, Cardiovascular, Metabolic. Key products include RYTARY.
IMPAX LABS at a Glance
- Strong track record with 98% execution quality across 15 trials
- Fast trial execution (19 months median completion)
IMPAX LABS's Key Drugs
IMPAX LABS's core commercial portfolio centers on RYTARY, CREXONT, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
IMPAX LABS's Recent FDA Approvals
IMPAX LABS secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
IMPAX LABS's Therapeutic Areas
IMPAX LABS's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IMPAX LABS's Top Competitors
IMPAX LABS's closest competitors by therapeutic-area and drug-target overlap include Merck, GE HEALTHCARE, and Novo Nordisk. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IMPAX LABS Pipeline Snapshot
IMPAX LABS has 14 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 4 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RYTARY leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 8/8 completed
- • Speed: 19 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (1)
Company Info
- First Approval
- 1967-08-09
- Latest
- 2026-06-18
- Applications
- 150
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges